Kornimate/medical-research-clean huggingface dataset:
pediatric speech therapy session frequency and speech outcomes

Conditions: Speech Therapy; Language Disorders in Children; Articulation Disorders in Children; Communication Disorder, Childhood; Pediatric; Mode of Therapy; Frequency of Therapy

Summary: the goal of this clinical trial is to compare speech therapy outcomes in children ages 18 months to 16 years who participate in weekly speech therapy with home programming versus every-other week speech therapy with home programming in outpatient speech therapy. the main question it aims to answer is: does a change in how often speech therapy sessions are delivered show an increased benefit in language and articulation standardized test scores? participants will be randomly assigned to either (1) weekly or (2) every-other-week speech therapy for a total of 8 sessions. researchers will compare these two groups to see if there are differences in speech outcomes.


Eligibility criteria:
inclusion criteria: * medical order for speech therapy * patients eligible for speech therapy at connecticut children's (qualify for receptive, expressive language and/or articulation therapy) * diagnosis of communication disorder.icd-10 codes will be utilized pertaining to expressive, receptive language and articulation disorders (icd-10 code specific to patient: f80.0, f80.1, f80.2, f80.4, f80.9, r47.89, r41.841) * patient recommended for individual (i.e. not group) treatment * 18 months to 16 years of age * completed 1 plan of care (poc) with a duration of 8 sessions * attended at least 80% of scheduled visits during their plan of care period (still completing 8 sessions of therapy, may have extended time to completion). * services for a full 8-session plan of care. exclusion criteria: * - seeking speech therapy care for treatment of disorders related to diagnosis of voice, feeding, fluency, and/or cognition * patient unable to complete standardized tests (eowpvt-4, rowpvt-4, gfta-3, reel-4) * patients in group speech therapy * patients younger than 18 months or older than 16 years of age * not willing to complete a full poc (8 sessions) * unable/unwilling to attend 80% of scheduled visits
ert remote health monitoring

Conditions: Pulmonary Disease, Chronic Obstructive; COPD; Chronic Obstructive Lung Disease; Bronchitis, Chronic; Pulmonary Emphysema

Summary: remote health monitoring (rhm) is the assessment of one's own symptoms at home between doctor visits, using things like at-home breathing tests, electronic diaries to answer questionnaires, and other monitoring devices. the hypothesis of this study is that the health and quality of life of people with copd who do rhm for one year will be better than people with copd who do not do rhm. subjects who are at least 40 years old, have been diagnosed with chronic obstructive pulmonary disease (copd), also known as chronic bronchitis or emphysema, and are current or former smokers will be invited to participate. this study is paid for by eresearch technology (ert). subjects will complete 2 visits at ucla, separated by one year of rhm. all subjects will participate in rhm. rhm will involve daily monitoring at home using a few electronic devices: blood oxygen levels, symptoms, medication use, breathing tests, and activity monitoring. visits will include physical exam and medical history, ecg, questionnaires, breathing tests, and exercise tests.


Eligibility criteria:
inclusion criteria: * age \>40 years. * clinical diagnosis of moderate to severe copd in accordance with the definition of the american thoracic society (ats).9 * smoking history \>10 pack-years. * postbronchodilator fev1/fvc\<70% and fev1\<70% based on nhanes iii reference values * domestic situation felt to be supportive of remote health monitoring. * ability to give informed consent. exclusion criteria: * clinical diagnosis of asthma. * pulmonary disease other than copd (e.g., lung cancer, sarcoidosis, active tuberculosis, bronchiectasis, pulmonary fibrosis, cystic fibrosis, or alpha-1-antitrypsin deficiency) or had lung volume reduction. * any other active disease that, in the opinion of the investigator, would put the safety of the subject at risk through study participation (e.g. unstable cardiovascular disease, renal failure, stroke). * previously diagnosed cancer is considered a significant disease unless it is in complete remission for 2 years at the initial visit. * any other disease that is life-threatening and carries a prognosis less than two years that, in the opinion of the investigator, is likely to influence the clinical course during the conduct of this trial. * myocardial infarction within 6 weeks of enrolment. * use of long-term oxygen therapy (ltot) prescribed for greater than 12 hours a day. * a known or suspected history of drug or alcohol abuse within 2 years prior to the initial visit.

Keywords: behavioral remote monitoring
diagnosis of acute appendicitis: low-dose computed tomography (ct) versus standard-dose ct

Conditions: Appendicitis

Summary: the purpose of this study is to determine whether low-dose ct is not inferior to standard-dose ct in the rate of unnecessary appendectomy.

acute appendicitis is a very common disease with the lifetime incidence of 7%. abdomen ct is an established first-line diagnostic test in patients suspected of having acute appendicitis. since many individuals suspected of having acute appendicitis are young, with a mean age of 30 years, ct radiation is of particular concern. the estimated lifetime attributable risk of death from cancer due to the radiation exposure of a single abdomen ct study is 2-7/10,000 for average adults ranging 20-40 years in age. the purpose of this study is to determine whether low-dose ct is not inferior to standard-dose ct in the negative appendectomy rate.

Eligibility criteria:
inclusion criteria: * suspected of having acute appendicitis * referred for abdomen ct from emergency department exclusion criteria: * body mass index \< 18.5 kg/m2 (ultrasonography is favored) * intravenous contrast-enhancement is contraindicated
itraconazole for the prevention of fungal infections in chronic granulomatous disease

Conditions: Mycoses

Summary: this protocol describes a prospective, randomized study examining the safety and efficacy of itraconazole for preventing fungal infections in patients with chronic granulomatous disease (cgd). cgd is a genetic disorder in which phagocytes are unable to produce oxygen radicals. as a result, affected patients are prone to recurrent, severe infections with bacterial and fungal organisms. patients with cgd of 5 or more years of age without evidence of infection at the time of study entry will be eligible for enrollment. patients will be randomized to receive itraconazole or placebo tablets daily, in a double blinded fashion. in addition to itraconazole, all patients will receive antimicrobial prophylaxis against bacterial infection, and may in addition receive gamma-interferon as prophylaxis against infection. randomization of patients will be stratified among patients receiving or not receiving gamma interferon. the primary endpoint of the study will be the development of culture or histologically proved invasive fungal disease. patients will be monitored every three months for evidence of drug toxicity. the anticipated accrual period will be approximately 36-48 months.

this protocol describes a prospective, randomized study examining the safety and efficacy of itraconazole for preventing fungal infections in patients with chronic granulomatous disease (cgd). cgd is a genetic disorder in which phagocytes are unable to produce oxygen radicals. as a result, affected patients are prone to recurrent, severe infections with bacterial and fungal organisms. patients with cgd of 5 or more years of age without evidence of infection at the time of study entry will be eligible for enrollment. patients will be randomized to receive itraconazole or placebo tablets daily, in a double blinded fashion. in addition to itraconazole, all patients will receive antimicrobial prophylaxis against bacterial infection, and may in addition receive gamma-interferon as prophylaxis against infection. randomization of patients will be stratified among patients receiving or not receiving gamma interferon. the primary endpoint of the study will be the development of culture or histologically proved invasive fungal disease. patients will be monitored every three months for evidence of drug toxicity, and surveillance cultures of nasopharynx and stool will be obtained. the anticipated accrual period will be approximately 36-48 months.

Eligibility criteria:
documented chronic granulomatous disease more than 5 years of age. no fungal infection within the past year. not currently on other antifungals or have taken other antifungals during the past 3 months. not currently on phenytoin or rifampin. negative pregnancy test within 2 weeks of starting protocol.

Keywords: aspergillosis phagocyte defect torulopsis chronic granulomatous disease
health-connected devices and physical activity recovery in bariatric surgery patients

Conditions: Obesity, Morbid; Bariatric Surgery Candidate

Summary: the goal of clinical trial is to evaluate the impact of use of health-connected devices and of an internet-based intensive follow-up on physical activity recovery during the 6-month period after bariatric surgery in obese patients.

90 patients with morbid obesity, having recently benefited from an act of bariatric surgery will be recruited for clinical trial if they meet the inclusion and no inclusion criteria. this is a single-center, open, controlled, randomized, 2 parallel-groups: * "mobility coaching" group * "diet coaching" group the "diet coaching" group will be the "control group" of "mobility coaching" group and vice versa. patients in both groups will be equipped with a connected-scale and a wristwatch equipped with a pedometer connected. the online tools available to patients will be used to motivate patients to progress and alert the coaches and the medical team in case of difficulties to achieve the objectives.

Eligibility criteria:
inclusion criteria: * primo-surgery bariatric surgery a week before their inclusion * absence of surgical side events related to the surgical procedure * adult female or male * weight ≤ 150 kg * knowing read and write french routinely, * possessing an internet connection at home, * possessing and knowing how to use a computer or tablet, * owning a smartphone, * affiliated with a social security scheme * not trust * having signed the informed consent letter non-inclusion criteria • patient with major disabilities causing a definitive loss of mobility exclusion criteria: • none

Keywords: nutrition physical activity bariatric surgery obesity health technology health-connected devices
danish carvedilol study in portal hypertension

Conditions: Cirrhosis; Portal Hypertension

Summary: patients with large esophageal varices who have not yet experienced bleeding, are normally treated with propranolol, a beta blocking agent that reduces the portal pressure and thereby diminish the risk of bleeding. 20-40% of the patients do not respond to this treatment or have to discontinue the treatment because of side effects. the aim of this study is to evaluate if carvedilol (a combined alfa -beta blocker) has better efficacy and safety than propranolol in lowering the portal pressure in patients with cirrhosis.


Eligibility criteria:
inclusion criteria: * cirrhosis * hvpg \> 12 mmhg exclusion criteria: * respiratory disease that contradict endoscopy * hepatic encephalopathy * hepatorenal syndrome * copd or asthma * treatment with vasoactive drugs within 1 week of inclusion * heart disease that contradict treatment with beta-blocking agents * iddm * pregnancy
a study of pmpa in hiv-infected patients

Conditions: HIV Infections

Summary: the purpose of this study is to see if it is safe and effective to give pmpa to hiv-infected patients. this study also examines how the body handles pmpa.


Eligibility criteria:
inclusion criteria patients must have: * laboratory diagnosis of hiv infection. * cd4 cell count \>= 200 cells/mm3 within 28 days prior to entry. * plasma hiv rna \>= 10,000 copies/ml within 28 days of entry. * minimum life expectancy of 12 months. exclusion criteria co-existing condition: patients with any of the following symptoms or conditions are excluded: * active, serious infections (other than hiv) that require parental antibiotic therapy. patients may be considered recovered if at least 2 weeks have elapsed following cessation of parental therapy before enrollment. * active clinically significant medical problems that include cardiac disease (e.g., symptoms of ischemia, congestive heart failure, or arrhythmia). * positive test for hepatitis b surface antigen or hepatitis c antibody in serum. patients with any of the following prior conditions are excluded: history of malignancy other than basal cell carcinoma or cutaneous kaposi's sarcoma. patients who are receiving: * antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents. * interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin b, cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin, systemic chemotherapeutic agents, systemic corticosteroids, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (probenecid) and other investigational agents. within 2 weeks prior to entry: * antiretroviral therapy, including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents. * interferon or interleukin therapy, aminoglycoside antibiotics, amphotericin b, cidofovir, diuretics, foscarnet, ganciclovir, itraconazole, fluconazole, ketoconazole (topical allowed), isoniazid, rifampin, rifabutin, clarithromycin, azithromycin, systemic chemotherapeutic agents, systemic corticosteroids, other agents with significant nephrotoxic potential, other agents that may inhibit or compete for elimination via active renal tubular secretion (probenecid) and other investigational agents. active drug or alcohol abuse as demonstrated by a positive screening test for drugs of abuse (except marijuana or drugs used for medical indications), or substance abuse considered sufficient to hinder patient compliance.

Keywords: placebos anti-hiv agents adenine
prevalence of primary aldosteronism among hypertensive patients with atrial arythmia

Conditions: Primary Aldosteronism; Atrial Fibrillation

Summary: atrial arrhythmia is the most frequent cardiac arrhythmia. it is a source of significant morbidity. hypertension is a major risk factor for atrial arrhythmias. primary hyperaldosteronism (pa) is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias with a specific, sometimes curative, treatment. the purpose of the study is to show that the prevalence of pa among hypertensive patients under 65 years old with atrial arrhythmia is high, justifying systematic screening.

atrial arrhythmia is the most frequent cardiac arrhythmia, affecting one million patients in france. it is a source of significant morbidity, a major deterioration in the quality of life and considerable health expenditure. hypertension is a major and modifiable risk factor for atrial arrhythmias. primary hyperaldosteronism is a common cause of secondary hypertension, associated with a high prevalence of arrhythmias, but also stroke, coronary artery disease, heart and kidney failure. this form has a specific treatment, sometimes curative. the objective of this study is to show that the prevalence of primary hyperaldosteronism among patients under 65 with atrial arrhythmias is high, justifying systematic screening in this population. the investigators will consecutively include 65-year-old hypertensive patients hospitalized in the department with atrialarrhythmia. they will benefit from an aldosterone to renin ratio assay under standardized conditions at 3 months. patients whose aldosterone (pmol/l) to renin (mui/l) ratio is greater than 64 will benefit from saline infusion test if necessary and adrenal scan. patients with a definite diagnosis who would prefer surgical treatment will benefit from adrenal venous catheterization.

Eligibility criteria:
inclusion criteria: * hypertensive patients aged of 18 to 65 years with atrial arrhythmia. exclusion criteria: * bmi above 30 * any situation where the discontinuation of treatments (including betablockers and diuretics) presents a risk according to the investigator
medicinal plant use for treating inflammation among dominicans in new york city and the dominican republic

Conditions: Inflammation

Summary: the purpose of this study is to investigate and compare the use of herbal medicine among dominicans in new york city and the dominican republic.

according to the 2000 u.s. census report, dominicans constitute the largest hispanic immigrant group in new york city. studies have shown that immigrants' use of traditional and herbal medicine is close to that of native-born americans. however, minority immigrants often have limited access to traditional health care; as a result, they may be more likely to consult with traditional healers and use medicinal plants than nonimmigrants. this study is designed to increase knowledge about immigrants' health and to contribute to more culturally-sensitive health care. the purpose of this study is to determine medical plant knowledge and use among dominican traditional healers and patients in new york city and in the dominican republic. this study will comprise two parts. in part i, dominican medicinal plant users and dominican traditional healers in new york city will be questioned about the medicinal plant species they know and how they are used for prevalent illnesses. the same number of participants will be interviewed in the dominican republic, allowing for detailed comparisons between the two study sites. in part ii, the most frequently-cited medicinal plant species will be subjected to a thorough literature review on their pharmacologic activity and the chemical composition of their active constituents. two in vitro assays will be used to measure the anti-inflammatory activity of certain plant extracts, and their anti-inflammatory compounds will be isolated and characterized for the purpose of standardization of active extracts. on the basis of these results, recommendations will be formulated for future studies and community use of selected medicinal plant species.

Eligibility criteria:
inclusion criteria: * dominican ethnicity * have knowledge of dominican medicinal plants

Keywords: complementary therapies plants, medicinal dominican republic hispanic americans
cutting-through at the greater tuberosity

Conditions: Rotator Cuff Tears

Summary: the investigators evaluated the correlation between cutting-through at the greater tuberosity (gt) just medial to the lateral knotless anchor in arthroscopic suture-bridge rotator cuff repair and the bone mineral density (bmd) of the lumbar spine, hip and gt of the proximal humerus and to evaluate factors and clinical outcomes related to cutting-through at the gt.

seventy-eight patients who underwent arthroscopic suture-bridge rotator cuff repair and who had undergone dual energy x-ray absorptiometry (dexa) scans before surgery were included. patients were divided into two groups: patients who had cutting-through (46, group i) and patients who did not (32, group ii). clinical and radiological data including demographics, bmds, fatty infiltration of rotator cuff muscles, tear size, tear involvement, vas pain score, and ases score were analyzed.

Eligibility criteria:
inclusion criteria: 1. primary arthroscopic repair for a symptomatic full-thickness rotator cuff tear identified by preoperative mri 2. dual energy x-ray absorptiometry (dexa) to evaluate the bmd of the lumbar spine and hip, as a standardized measurement, and the gt of the affected proximal humerus 3. follow up for a minimum of 2 years after the primary surgery. exclusion criteria: 1. primary arthroscopic repair due to partial-thickness rotator cuff tear or an isolated subscapularis tear 2. primary suture-bridge repair with 3 or more lateral-knotless anchors 3. previous history of fractures or surgeries on the affected shoulder 4. shoulder instability 5. glenohumeral osteoarthritis 6. neurologic or systemic disease diseases influencing the shoulder joint 7 history of infection of the shoulder joint

Keywords: rotator cuff tear cutting-through bone mineral density suture-bridge repair
using upper limb rehabilitation robot in stroke patient rehabilitation

Conditions: Stroke; Rehabilitation

Summary: a robot arm for upper limb rehabilitation is intended to achieve rehabilitation effects through the study of robot control theory and the integration of sensors such as semg. the goal is to reduce the workload of rehabilitation therapists.

ntuh-ii is an upper limb rehabilitation robot. the aim of this robot is to reduce the workload of rehabilitation therapists and make the rehabilitation process more effective. the robot can complete rehabilitation tasks, such as elbow flexion/extension, shoulder flexion/extension, and shoulder horizontal abduction/adduction, etc. by giving the desired trajectory, the robot can lead patients to do the tasks in passive mode or active mode. however, curative rehabilitation should include the motion intention of patients. this study aimed to investigate the efficacy of rehabilitation effect by combining the sensors (such as semg, imu) to obtain the motion intention of patients and give the assistive movement.

Eligibility criteria:
inclusion criteria: 1. first-time stroke, occurring between 2 weeks and 2 years after onset, resulting in unilateral hemiplegia. 2. able to understand and follow simple instructions. 3. able to maintain a sitting posture balance. 4. rank on the brunnstrom scale is between two and five. 5. both ischemic and hemorrhagic strokes are included. exclusion criteria: 1. not yet fully conscious. 2. suffering from a psychiatric disorder or post-stroke psychiatric abnormalities. 3. cognitive or behavioral impairments that affect the ability to comprehend or execute the experimental tasks. 4. severe aphasia preventing compliance with researchers' instructions for this study. 5. medical conditions in internal medicine that jeopardize patient safety, such as severe heart or lung diseases, or patients requiring bed rest. 6. patients with a severe systemic illness requiring bed rest. 7. patients with shoulder joint pathology unable to undergo exercise therapy. 8. patients with severe osteoporosis who have concerns about fractures during physical activity. 9. patients with arrhythmia and implanted cardiac pacemakers. 10. severe uncontrolled seizures that cannot be improved with medication, physical therapy, botulinum toxin injections, or phenol block procedures.